J
John Varigos
Researcher at Population Health Research Institute
Publications - 5
Citations - 10533
John Varigos is an academic researcher from Population Health Research Institute. The author has contributed to research in topics: Randomized controlled trial & Aspirin. The author has an hindex of 2, co-authored 3 publications receiving 9629 citations.
Papers
More filters
Journal ArticleDOI
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Salim Yusuf,Steven Hawken,Stephanie Ôunpuu,Tony Dans,Alvaro Avezum,Fernando Lanas,Matthew J. McQueen,Andrzej Budaj,Prem Pais,John Varigos,Liu Lisheng +10 more
TL;DR: Abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, consumption of fruits, vegetables, and alcohol, and regular physical activity account for most of the risk of myocardial infarction worldwide in both sexes and at all ages in all regions.
Journal ArticleDOI
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
Active W Investigators,Stuart J. Connolly,Salim Yusuf,A Budaj,John Camm,Susan Chrolavicius,Patrick J. Commerford,Marcus Flather,Keith A.A. Fox,Robert G. Hart,S H Hohnloser,Campbell D. Joyner,Marc A. Pfeffer,Inderjit Anand,Heather M. Arthur,A Avezum,M Bethala-Sithya,Mel Blumenthal,L Ceremuzynski,R. De Caterina,Rafael Diaz,Gregory C. Flaker,G Frangin,M-G Franzosi,Christophe Gaudin,Sergey P. Golitsyn,Samuel Z. Goldhaber,Christopher B. Granger,David A. Halon,Antonio G. Hermosillo,David M. Hunt,Petr Jansky,Nicholas Karatzas,Matyas Keltai,Fernando Lanas,C P Lau,J-Y Le Heuzey,Basil S. Lewis,João Morais,Carlos A. Morillo,Ali Oto,Ernesto Paolasso,Ron J.G. Peters,M Pfisterer,Leopoldo S. Piegas,T Pipillis,C Proste,Eva Sitkei,Karl Swedberg,David Synhorst,Mario Talajic,V Trégou,Vicent Valentin,W. Van Mieghem,William S. Weintraub,John Varigos +55 more
TL;DR: Clopidogrel plus ASA plus irbesartan will lead to a new understanding of the role of combined antiplatelet therapy and therole of blood pressure lowering with an angiotensin II receptor blocker in patients with AF.
Journal ArticleDOI
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Christina Reith,Colin Baigent,L Blackwell,Jonathan Emberson,Enti Spata,Kelly Davies,Heather Halls,Lisa Holland,Kate Wilson,Jane Armitage,Charlie H.S. Harper,David Preiss,Alistair J. Roddick,Anthony C Keech,John Simes,Rory Collins,Elizabeth H Barnes,Jordan Fulcher,William G. Herrington,Adrienne Kirby,Borislava Mihaylova,Rachel O'Connell,Pierre Amarenco,Philip J. Barter,D. J. Betteridge (deceased),Michael A. Blazing,Jackie Bosch,Louise Bowman,Eugene Braunwald,Christopher P. Cannon,Michael Clearfield,Stuart M. Cobbe,Helen M. Colhoun,Björn Dahlöf,Barry Davis,James L. de Lemos,John R. Downs,Paul N. Durrington,Bengt Fellström,Ian Ford,MariaGrazia Franzosi,John Fuller (deceased),Curt D. Furberg,Robert J. Glynn,David Gordon,A. Gotto Jr.,Richard Grimm,Ajay Gupta,C. Morton Hawkins,Graham A. Hitman,Hallvard Holdaas (deceased),A.D Jardine,J. Wouter Jukema,John J.P. Kastelein,Sharon Kean,John Kjekshus,Genell Knatterud (deceased),Robert H Knopp (deceased),Wolfgang Koenig,M. Koren,Vera Krane,Martin J Landray,John C. LaRosa,Roberto Latini,Eva Lonn,Donata Lucci,Jean G. MacFadyen,Peter W. Macfarlane,Stephen MacMahon,Aldo P. Maggioni,Roberto Marchioli,Ian C. Marschner,Lemuel A. Moyé,Sabina A. Murphy,Andrew Neil,Enrico Nicolis,Chris J. Pickard,Sarah Parish,Terje R. Pedersen,Richard Peto,Marc A. Pfeffer,Neil R Poulter,Sara L. Pressel,Jeffrey L. Probstfield,Mahboob Rahman,Paul M. Ridker,Michele Robertson,F K Sacks,Naveed Sattar,Roland E. Schmieder,Patrick W. Serruys,Peter S. Sever,John Shaw (deceased),James Shepherd (deceased),Lara M. Simpson,Peter Sleight (deceased),Luigi Tavazzi,Gianni Tognoni,Andrew Tonkin,Stella Trompet,Christoph Wanner,Hans Wedel,Stephen E. Weis,K.M.A. Welch,Harvey Edward White Jr.,John Wikstrand,Lars Wilhelmsen,Stephen D. Wiviott,Robin Young,Salim Yusuf,Faiez Zannad,Hiroyuki Arashi,Robert P. Byington,Robert Clarke,Marcus Flather,Uri Goldbourt,S. Goto,Jemma C. Hopewell,Kees Hovingh,Patricia M. Kearney,George D. Kitas,Connie B. Newman,Marc S. Sabatine,G G Schwartz,Liam Smeeth,Jonathan A. Tobert,John Varigos,Junichi Yamaguchi +127 more
TL;DR: An individual participant data meta-analysis of all recorded adverse muscle events in large, long-term, randomised, double-blind trials of statin therapy found a small, clinically insignificant increase in median creatine kinase values of approximately 0·02 times the upper limit of normal.
Journal ArticleDOI
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
John W. Eikelboom,Jackie Bosch,Stuart J. Connolly,Jessica Tyrwitt,Keith A.A. Fox,Eva Muehlhofer,Christoph Neumann,Christoph Tasto,Shrikant I. Bangdiwala,Rafael Diaz,Marco Alings,Gilles R. Dagenais,Darryl P. Leong,Eva Lonn,Alvaro Avezum,Leopoldo S. Piegas,Petr Widimsky,Alexander Parkhomenko,Deepak L. Bhatt,Kelley R. Branch,Jeffrey L. Probstfield,Patricio Lopez-Jaramillo,Lars Rydén,Nana Pogosova,Katalin Keltai,Matyas Keltai,Georg Ertl,S Stoerk,Antonio L. Dans,Fernando Lanas,Yan Liang,Jun Zhu,Christian Torp-Pedersen,Aldo P. Maggioni,Patrick J. Commerford,Tomasz J. Guzik,Thomas Vanassche,Peter Verhamme,Martin O'Donnell,Andrew Tonkin,John Varigos,Dragos Vinereanu,Camillo Felix,Jae-Hyung Kim,Khairul Shafiq Ibrahim,Basil S. Lewis,K. Metsarinne,Victor Aboyans,Philippe Gabriel Steg,Masatsugu Hori,Ajay K. Kakkar,Sonia S. Anand,Andre Lamy,Mukul Sharma,Salim Yusuf +54 more
TL;DR: In patients with chronic coronary artery disease and/or peripheral artery disease (PAD), extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals as mentioned in this paper .
Clinical Research Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
Eva M. Lonn,Jackie Bosch,J Pogue,Álvaro Avezum,Irina Chazova,Antonio Filipinas Dans,Rafael Diaz,George Fodor,Petr Jansky,Matyas Keltai,Katalin Keltai,Kamlesh Kunti,Jae-Hyung Kim,Lawrence A. Leiter,Basil Lewis,Lisheng Liu,Patricio Lopez-Jaramillo,Prem Pais,Alexandr Parkhomenko,Leopoldo S. Piegas,Christopher M. Reid,Karen Sliwa,William D. Toff,John Varigos,Denis Xavier,Khalid Yusoff,Jun Zhu,Gilles R. Dagenais,Salim Yusuf +28 more
TL;DR: In this article, the authors showed that cholesterol and blood pressure can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular events by 20%-30% within 5 years in high-risk individuals.